Tiziana Life Sciences Ltd
TLSA2.421USD
+0.041+1.72%
Horário de mercado （ET）Cotações atrasadas em 15 min
269.85MValor de mercado
--P/L TTM
Mais detalhes de Tiziana Life Sciences Ltd Empresa
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
Informações da empresa
Código da empresaTLSA
Nome da EmpresaTiziana Life Sciences Ltd
Data de listagemNov 20, 2018
CEOMr. Ivor Elrifi
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 20
Endereço- -
Cidade- -
Bolsa de valoresNASDAQ Capital Market Consolidated
País- -
Código postal- -
Telefone- -
Site- -
Código da empresaTLSA
Data de listagemNov 20, 2018
CEOMr. Ivor Elrifi
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 14 de jun
Atualizado em: sáb, 14 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cerrone (Gabriele M)
37.71%
Chernett (Jorey)
5.34%
Dauntless Investment Group, LLC
1.56%
Jane Street Capital, L.L.C.
0.15%
OMERS Administration Corporation
0.13%
Other
55.10%
Investidores
Investidores
Proporção
Cerrone (Gabriele M)
37.71%
Chernett (Jorey)
5.34%
Dauntless Investment Group, LLC
1.56%
Jane Street Capital, L.L.C.
0.15%
OMERS Administration Corporation
0.13%
Other
55.10%
Tipos de investidores
Investidores
Proporção
Individual Investor
43.06%
Investment Advisor
2.04%
Research Firm
0.26%
Investment Advisor/Hedge Fund
0.25%
Pension Fund
0.13%
Hedge Fund
0.04%
Other
54.22%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
68
51.04M
45.79%
+9.50M
2025Q1
69
45.10M
40.46%
+3.34M
2024Q4
64
40.33M
36.45%
-5.07M
2024Q3
58
41.30M
37.43%
-3.04M
2024Q2
51
40.27M
36.45%
-4.04M
2024Q1
48
40.16M
36.35%
-4.27M
2023Q4
52
45.25M
44.24%
+1.19M
2023Q3
58
45.24M
44.24%
+1.10M
2023Q2
54
45.32M
44.32%
+1.19M
2023Q1
53
45.06M
44.06%
+868.09K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cerrone (Gabriele M)
42.04M
37.71%
+2.70M
+6.85%
Mar 31, 2025
Chernett (Jorey)
5.95M
5.34%
+5.95M
--
Jun 11, 2025
Dauntless Investment Group, LLC
1.74M
1.56%
+1.74M
--
Mar 31, 2025
Jane Street Capital, L.L.C.
167.54K
0.15%
+151.86K
+968.24%
Mar 31, 2025
OMERS Administration Corporation
144.90K
0.13%
+144.90K
--
Mar 31, 2025
HSBC Global Asset Management (UK) Limited
105.36K
0.09%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
92.57K
0.08%
+18.20K
+24.47%
Mar 31, 2025
Zhang Financial LLC
96.26K
0.09%
+3.07K
+3.30%
Mar 31, 2025
Kovitz Investment Group Partners, LLC
79.36K
0.07%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
77.89K
0.07%
-167.84K
-68.30%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Jul 16, 2020
Split
1>2.5
Data
Tipo
Proporção
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Oct 20, 2021
Merger
2<1
Jul 16, 2020
Split
1>2.5
